



(ASOM)

Acute (50)
 Suppurative Otitis Media (ASOM)
 5- 1) 2007 2006 (

Staphylococcus aureus %49.23
Proteus vulgaris % . *Candida albicans*
 B-haemolytic streptococci % . *Pseudomonas aeruginosae* % .
clocae Staph. epidermidis Haemophilous influenzae Pneumoniae Klebsiella
 .% . *Moraxella catarrhalis Enterobacter*
 % %

%96.87 Amikacin Vancomycin *Staph. aureus*
 % Ciprofloxaci % . Tobromycin % 78.12
Proteus vulgaris . % . Lincomycin

Amikacin % Tobromycin % Vancomycin
 Tetracyclin % Ciprofloxacin

Pseudomonas aeruginosa .%

Tetracyclin % Amikacin Vancomycin
 Tobromycin % . Ciprofloxacin

Amikacin % .
Staph. aureus (Tetracyclin Ciprofloxacin Tobromycin)
 Tobromycin % . Amikacin
Staph. aureus (Tetracyclin Ciprofloxacin Amikacin)
 Amikacin % . Tobromycin

Proteus vulgaris (Tetracyclin Ciprofloxacin Tobromycin)
 Amikacin) Tobromycin % . Amikacin
Proteus vulgaris (Tetracyclin Ciprofloxacin
Candida albicans .Tobromycin

Miconazole . (. .) Nystatin
 (. .) Ketoconazole (. .)

Griseofulvin (. .) Fluconazole
 . ()

ISOLATION AND IDENTIFICATION SOME THE PATHOGENIC AGENTS FROM ACUTE SUPPURATIVE OTITIS MEDIA (ASOM) IN CHILDREN IN AL-DIWANIYA CITY AND THEIR SENSITIVITY TEST AGAINST SOE OF ANTIBIOTICS IN VITRO

Ebtesam Thamer J., Enas Mohamad M

Department of Biology, college of Education, university of Al Qudisyia. Qudisyia-Iraq.

Apstract

The present study entalid collection of (50) ear swabs from children patients suffering from Acute suppurative Otitis Media (ASOM) carried at the E.N.T section of the teaching hospital in AL-Diwaniya a City. Whose ages ranged between (1 day-5 years) during the Period from October 2006 until Jun 2007. The aim of these study is to isolate dominant pathogenic causes and responsible of (ASOM) in Children and effect of some antibiotics on this causes. *Staphylococcus aureus* bacteria was the dominant cause of Acute suppurative otitis media with the percentage of 49. 23%. Followed by *Candida albicans* with the percentage of 30.76%, *Proteus vulgaris* 6.15%, *Pseudomonas aeruginosa* 4.61 B-haemolytic streptococci, *Klebsiella Pneumoniae* Haemophilous influeenzae, *Staphylococcus epidermidis*, *Enterobacter clocase*, *Moraxella catarrhalis* with percentage 1.53% Results showed that 80% of the infection cases were caused by one pathogenic factor and 20% of them but more than one factor. The sensitivity test showed that *staph. aureus* bacteria had the highest Sensitivity to vancomycin 96.87%, Amikacin 78.12%, Tobromycin 68.74% and ciprofloxacin 65%, While showed lowest sensitivity to Lincomycin 3.12% while *Proyeus vulgaris* showed highest sensitivity to vancomycin 100%, Trobromycin 75%, Amikacin and ciprofloxacin with other antibiotic 50% and showed lowest sensitivity to Tetracyclin with other antibiotics 25%. *Pseudomonas aeruginosa* bacteria showed highest sensitivity to vancomycin and Amikacin 100%. Tetracyclin and ciprofloxacin with other antibiotics 66.66% while showed lowest sensitivity to Tobramycin and other antibiotics 33.33%. the results of synergistic antibiotics effect on *Staph aureus* showed the effect between Amikacin with (Tobramycin, ciprofloxacin and tetracycline) had a parentage of 90.47% whilethe synergistic, effect between Tobromycin and (Amikacin , ciprofloxacin and Tetracycline) had a percentage of 42.85%. While synergistic effect on *Proteus vulgaris* showed the effect between Amikacin with (Tobromycin, ciprofloxacin and Tetracycline) had percentage of 50%. While synergistic effect between Tobromycin and (Amikacin, ciprofloxacin and Tetracycline) had a percentage of 66.66%. The results showed that *Candida albicans* isolates had the highest sensitivity to Nystatin with inhibition zone rate (10, 11.8, 18.76) mm, Miconazole (0, 8, 15.3) mm, ketoconazole (10, 9.6,14.94) mm, Fluconazole (0, 9.6, 12.6) mm, Griseofulvin (0, 0, 6) mm.

[]
 [4] Behrman
 Himedia MacCkoney agar
 Blood agar (India) Laboratories
 (England) Mast Collee .[5]
 -18 ° 37 []
 24
 ()
 [6] Mattila and Joki
 .[16 15 14 13 12 11]
 [6] Ereshewtz
 Ciprofloxacin (England) Oxoid .[7]
 Cifixime ()
 Amikacin Cefotaxime Ceftazidime () (2)
 Staph. .Bioanalyse (France) . [8]
 aureus [6] Mattila and Joki
 .[17] (-)
 .[18]
 (Candida)
 [19] Bauer (Opporutunistic Pathogens)
 -: .[9]
 Nutrient agar

Materials and Methods

() (50)
 -)
 (Micropipete) (5
 2007 2006
 .[10] Indudharan
 %70

العدد الكلي للعزلات المشخصة = ٦٥ عزلة

Staph.aureus

%49.23

[23]

Staph.aureus

(CBCPAB)

Candida Bromo-cresol Purple Agar Base

Sabouroud (SDA)

dextrose agar

[24]

52

[25]

[20]

%

Candida albicans [27 26]

[21]

[28] %

Micon- Fluconazole Ketaconazole Nystatin

%78.08

Griseofulvin zole

Proteus vulgaris

[25] %

[29] Gupte %6.9

[22]

[30]

Results and Discussion

Elastase Alkaline Protease

(20)

(45)

Serine Protease

(50)

Candida albicans

%

P.aeruginosa

[25]

%

Klebsiella streptococc B-haemolytici
Haemophilous influenzae pneumoniae
Enterobacter epidermidis Staphylococcus
catarrhalis Moraxella clocae

B-

[25]


%

Candida albicans

النسبة المئوية %	عددها	العزلات المشخصة
%٤٩.٢٣	٣٢	<i>Staphylococcus aureus</i>
%٣٠.٧٦	٢٠	<i>Candida albicans</i>
%٦.١٥	٤	<i>Proteus vulgaris</i>
%٤.٦١	٣	<i>Pseudomonas aeruginosa</i>
%١.٥٣	١	<i>B-haemolytic streptococci</i>
%١.٥٣	١	<i>Klebsiella pneumoniae</i>
%١.٥٣	١	<i>Haemophilous influenzae</i>
%١.٥٣	١	<i>Staphylococcus epidermidis</i>
%١.٥٣	١	<i>Enterobacter clocae</i>
%١.٥٣	١	<i>Moraxella catarrhalis</i>


[32] David .
Staph aureus
 .
 . [33]
 Proteus vulgaris .
 Vancomycin
 % Tobromycin %
 Ciprofloxacin Amikacin
 Chloramphenicol PenicillinG Ceftriaxone
 % Lincomycin
 .% Tetracyclin
 Pseudomonas aeruginosa
 Vancomycin
 % Amikacin
 Ciprofloxacin Tetracycline
 Peni-cillinG Streptomycin Ampicillin
 Clindamy-cin rimethoprim Erythromycin
 Rif- Cephalothin Cefotaxim Lincomycin
 % . ampicin
 Tobromycin
 % .

haemolytic streptococci
 % .
Enterobacter clocae
Haemophilous Klebsiella pneumoniae
Staphylococcus epidermidis influenzae
 [27] Barton .%
Haemophilous Streptococcus pneumoniae
 Prellner *Moraxella catarrh-lis influenzae*
Haemophilous [31]
Streptococcus pneumoniae influenzae
 Moraxella catarrh-alis هي مسببات رئيسية مهمة
 لاصابات الاذن الوسطى القيحي الحاد ولجميع الفئات العمرية
 ()
 % () %
 C. = ()
 % *Staphylococcus aureus+ albicans*
Staph. aureus + Pseudomonas = ()
Staph. = % *aeruginosa*
 .% *aureus+ Proteus vulgaris*
Staph. aureus
 Vancomycin
 % . Amikacin % .
 Ciprofloxacin % . Tobramycin
 Neomycin Tetracyclin %
 % .
 % . Lincomyin



Staph. aureus

:



Proteus vulgaris


:()

E:Erythromycin
C:Chloramphenicol
GN:Gentamycin
CM:Clindamycin
AMX:Amoxicillin
PG:Penicillin G
L:Lincomycin
RD:Rifampicin

S:Streptomycin
AN:Amikacin
AM:Ampicillin
F:Nitrofurantion
CRO:Ceftriaxone
ZAZ:Ceftazidime
W:Trimethoprim

VA:Vancomycin
CLT:Cephalothin
CF:Ciprofloxacin
TE:Tetracyclin
N:Neomycin
CFM: Cifixime

CTX:Cefotaxime
TOB:Tobramycin



المضادات الحيوية

Pseudomonas aeruginosa

+	-	+	٥
-	-	+	٦
-	-	-	٨
-	-	+	٩
-	+	-	١٠

Proteus vulgaris

Amikacin

(Tetracyclin Ciprofloxacin Tobromycin)

Amikacin

% .

Tobromycin

(Tetracyclin Ciprofloxacin Amikacin)

.Tobromycin

Candida albicans

C. albicans

Nystatin

/

(. .)

)

Miconazole

Ketoconazole

(.

Fluconazole

(. .)

(. .)

Griseofulvin

()

Nystatin

[]

Murray

Ergosterol Sterole

Proteus vulgaris

Tobromycin Amikacin

Tobromycin +	Tobromycin +	Tobromycin +	Amikacin +	Amikacin +	Amikacin +		
Tetracyclin	Ciprofloxacin	Amikacin	Tetracyclin	Ciprofloxacin	Tobromycin		

: ()

Synergistic effect

Staph.

aureus

Amikacin

Tetracyclin, Ciprofloxacin,

Tobramycin

Amikacin

2

. % .

Amikacin

:2

Staph. aureus

Amikacin +	Amikacin +	Amikacin +	رقم العزلة
Tetracycline	Ciprofloxacin	Tobromycin	
+	+	-	١
+	+	+	٢
+	+	+	٣
+	+	+	٤
+	+	+	٥
+	+	+	٦
+	+	-	٧

Tobromycin

Amikacin

Tetracycline Ciprofloxacin

Tobromycin

Staph. aureus

. % .

Tobromycin

:

Staph. aureus

Tobromycin +	Tobromycin +	Tobromycin +	عزلات بكتريا Staph. aureus
Tetracycline	Ciprofloxacin	Amikacin	
-	+	+	١
-	+	+	٤

			-	-	+		<i>Proteus vulgaris</i>
			-	+	+		
+	-	+					

- + حصول تآزر
- - عدم حصول تآزر

C. albicans

:

Griseofulvin			Miconazole			Nystatin			Ketoconazole			Fluconazole			مضادات الحياة
١٠٠٠	١٠٠	١٠	١٠٠٠	١٠٠	١٠	١٠٠٠	١٠٠	١٠	١٠٠٠	١٠٠	١٠	١٠٠٠	١٠٠	١٠	التركيز مايكروغرام/مل
٦	٠	٠	١٥.٣	٨	٠	١٨.٧٦	١١.٨	١٠	١٤.٩٤	٩.٦	١٠	١٢.٦	٩.٦	٠	عزلات خميرة <i>C. albicans</i>

Ceftriaxone 30	≥	≤	
Neomycin 10	≥	≤	
Tetracyclin 30	≥	≤	
Amikacin 30	≥	≤	
Streptomycin 10	≥	≤	
Erythromycin 15	≥	≤	
Nitrofurantion 300	≥	≤	
Trimethoprim 1.25	≥	≤	
Rifampicin 5	≥	≤	
Tobromycin 10	≥	≤	
Cephalothin 30	≥	≤	

Miconazole

Cytochrome-demethylase

Ergosterol Lanosterol

.[]

:6

1. Brook, I. **1998**. Microbiology of common infections in the upper respiratory tract. *Primary C*, **25**:633-648.
2. MIDDLE EAR INFECTIONS (MEI). 2006. Acute otitis media. *J. Medicine*. **20**(6):1-4.
3. AMERICAN ACADEMY of PEDIATRICS. (AAP). **2004**. *Diagnosis and management of acute media*. **113**(5): 1-20.
4. Behrman, R.E.; Kligman, R.M. and Jenson, H.B. **2000**. *Nelson textbook of pediatrics*. 16th- ed. W.B. Saunders Company. Philadelphia, London, Toronto, sudney and Tokyo.
5. Hemli, C.; Brauner, A.; Carenfelt, C. and Wretlind, B. **1994**. Nasopharyngeal flora in Otitis Media with effusion. *Act atolaryngol*. **111**: 556- 561.
6. Mattila, P. S. and Joki, E. V. **2003**. Does adenoidectomy prevent recurrent otitis in young Children. *J. Midicine*. **128**: 163- 168.

/			
	≥	≤	
Ampicillin 10	≥	≤	
Chloramphenicol 30	≥	≤	
Penicillin G 10	≥	≤	
Clindamycin 2	≥	≤	
Amoxicillin 10	≥	≤	
Cifixime 5	≥	≤	
Ceftazidime 30	≥	≤	
Gentamicin 10	≥	≤	
Vancomycin 30	≥	≤	
Cefotaxime 30	≥	≤	
Lincomycin 15	≥	≤	
Ciprofloxacin 5	≥	≤	

21. McGinnis, M. R. **1980**. *Laboratory hand book of medical mycology*. Academic Press. New York.
22. Hindler, J. **1998**. *Antimicrobial susceptibility testing In: Essential Procedures for Clinical Microbiology Press*. Washington U. S. A.
23. Blueston, C. D. and Klein, J. O. **1995**. Clinical practise guid line on otitis media with effusion in young children. *J. Otolaryngology. Head - neck - surgery* **112**(4): 507-511.
24. Blueston, C. D. and Stool, S.E. **1983**. *Pediatric otolaryngology. W. B. Saunders Co. Philadelphia*: pp.370-527.
٢٥. الرماحي، سيوف خومان علوان. ٢٠٠٦. دراسة بكتيرية ومناعية على مرضى خمج الأذن الوسطى في محافظة القادسية، رسالة دكتوراه - كلية التربية - جامعة القادسية.
26. Rodrigues, W. J.; Schwartz, R.H. and Thorne, M. M. **1995**. Increasing incidence of penicillin-and ampicillin resistant middle ear pathogens. *Pediatr. Infect. Dis. J.* **14**:1075-1078.
27. Burton, M.; Leighton, S.; Robson, A. and Russel, J. **2000**. *Hall and Colmans diseases of the ear, nose and throat*. 15th. Ed. Churchill Livingstone. P.34.
٢٨. الشبلي، ماجد كاظم عبود. ٢٠٠٦. تأثير العزلات السريرية لخميرة المبيضات *Candida spp* دراسة بايولوجية ونسجية مرضية في محافظة الديوانية، رسالة دكتوراه - كلية التربية - جامعة القادسية.
29. Gupte, S. **1995**. *Short textbook of medical microbiology*. 6th- ed. Brothers Medical Publishers (P) LTD, Indian.
30. Avidano, M. A.; Cotter, C. S.; Stringer, S. P. and Schultz, G.S. **1998**. Analysis of protease activity in human otitis media. *Otolaryngol. Head-Neck-Surg.* **719**, 4: 346-351.
31. Prellner, K.; Kahimeter, G.; Marchisio, P. and Giebing, G. S. **1999**. Update of microbial problems in pediatric otolaryngology. *plenary session. Int. J. pediatr. otolaryngol* **49**:531-533.
32. David, L.; paterson, C.K.; Gottoberg, A. V.; Casellas, J. M.; Mulazimoglu, L.; Klugman, K.P.; Bonomo, R. A.; Rice, L. B. **2001**. Outcome of cephalosporin treatment. *J. Clin. Micro.* **39**: 2206-2212.
33. Mims, C.; Dockvell, H.M.; Goering, R.V.; Roitt, L.; Wakelin, D. and Zuckerman, M. **2004**. *Medical microbiology*. 3th. -ed. Mosby Company, U.S.A.
34. Rex, J. H.; Pflfer, M.A.; walsh, T. J.; Gosey, L. L. and Odds, F.C. **2001**. Antifungal
7. Ershevtz, R.A. **2003**. Adjunctive treatment for (AOM) in children. *J. Medicine. pediatr*, 2003.
8. Rovers, M. M.; Glaszion, P. and Appelmal, C. L. **2006**. Antibiotics for acute otitis media. *B. M. J.* **368**: 1429-1435
9. Roberts, S. Q. and Mackenzie, D. W. **1986**. *Text book of dermatology*. Black Well. Scientific publication. London.
10. Indudharan, R. and Ashrafal, J. H. **1996**. Use of Pre- reduced swab in bacteriology of Chronic Suppurative Otitis Media. *J. Of Laryngology and Otology.* **11**: 950 - 951.
11. Atlas, R.M.; Brown, A.E and Parks, L.C. **1995**. *Experimental microbiology*. Laboratory manual, Mosby- Year Book, Inc, London.
12. Collee, J. G; Fraser, A. G; Marmion, B. p. and Simmons, A. S. **1996**. *Practical medical microbiology*. 14th ed. Churchill living stone, New York
13. Forbes, B. A; Saham, D. F; and Weissfeld, A. S. **1998**. *Bailey and Scott's diagnostic microbiology*. 10th-ed. Mosby.
14. Koneman, E. W.; Allen, S. D.; Janda, W. M.; Srekenberger, P. C. and Winn, W. C. **1997**. *Diagnostic Microbiology*. 5th .ed Lippincott. Raven Publishers, Philadelphia, U. S. A.
15. Lennette, E. H.; Balows, A.; Hausler, W. J. and Schadomy, H. J. **1985**. *Manual of clinical microbiology*. American Society for Microbiology, Washinton. D. C.
16. Murray, P. P.; Baron, E. J.; Pfaller, M. A.; Tenover, F. C. and Tenover, R. H. **1999**. *Manual of clinical microbiology*. 7th-ed. Washington, USA.
17. Vandepitte, L.; Engbac, K. P. and Heuck, C. **1991**. *Basic laboratory procedures in clinical bacteriology*, Geneva.
18. National Committee for Clinical Laboratory Standards (NCCLS). **2001**. *Performance for antimicrobial susceptibility testing*. Wayne, pa.
19. Bauer, A. W.; kirby, W.M.; Sherris, J. C. and Turch, M. **1966**. Antibiotic susceptibility testing by standardized single disk method. *Americ. AM. J. Clin. Pathol.* **45**:493-496.
20. Baron, E.J.; Peterson, L.R. and Finegold, S.M. **1994**. *Bailey and scott. Diagnostic microbiology*. 9th Ed. The C.V. Mosby Company U.S.A, pp.401-403.

14(4): 643-658.

susceptibility testing. *Clinical. Microbiol.*